The Foundation for Orthopaedics and Regenerative Medicine
This trial will study the safety and efficacy of intranasal instillation of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes for the treatment of Parkinson's Disease
This patient funded trial aims to study the safety and efficacy of intranasal installation of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes for the treatment of Parkinson's Disease. Patients will receive a dose of 4 CCs of AlloEx, approximately 800 billion exosomes, between both nasal cavities. A second equivalent dose will be administered on the subsequent day. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.
Inclusion Criteria: * Diagnosis of Parkinson's Disease * Understanding and willingness to sign a written informed consent document Exclusion Criteria: * Active infection * Active cancer * Chronic multisystem organ failure * Pregnancy * Clinically significant Abnormalities on pre-treatment laboratory evaluation * Medical condition that would (based on the opinion of the investigator) compromise patient's safety. * Continued drug abuse * Pre-menopausal women not using contraception * Previous organ transplant * Hypersensitivity to sulfur * Anticoagulation medicine use
cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes
Arctuva estimate
Verify or correct the compensation shown for this listing.